Company intelligence / Profile preview

Orocidin A

Leuven, Belgium

Ownership: Private
Development stage: Other

Overview

Orocidin was a Belgian biotechnology company focused on the development of novel therapeutics for oral health and infectious diseases. The company's lead candidate, Orocidin A, was a peptide-based antimicrobial designed to treat oral mucositis and fungal infections in immunocompromised patients. Despite early-stage development efforts and participation in European biotech incubators, the company is no longer active and its programs have ceased development.

Therapeutic areas: Infectious DiseasesGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Orocidin A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orocidin A.

Explore the full profile